Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association.
about
Warfarin initiation nomograms for venous thromboembolismWarfarin initiation nomograms for venous thromboembolismWarfarin initiation nomograms for venous thromboembolismMarine Non-Glycosaminoglycan Sulfated Glycans as Potential PharmaceuticalsThe REG1 anticoagulation system: a novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndromeAnticoagulation in the management of non-ST-segment elevation acute coronary syndrome.Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention.A data-driven approach to optimized medication dosing: a focus on heparinHeparin-induced thrombocytopenia: pathophysiology and management.RNA aptamers as reversible antagonists of coagulation factor IXa.Heparin-induced thrombocytopenia and cardiovascular patients: recognition and treatment.Pharmacology and clinical use of recombinant activated factor seven in neurosciences.Thrombocytopenia in patients treated with heparin, combination antiplatelet therapy, and intra-aortic balloon pump counterpulsation.Heparin-dependent antibodies and thrombosis without heparin-induced thrombocytopenia.Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: implications for HIT pathogenesis.Diversity-oriented fluorescence library approach for the discovery of sensors and probes.Analysis of multiple factors involved in acute progressive cerebral infarction and extra- and intracranial arterial lesions.Unique extracellular matrix heparan sulfate from the bivalve Nodipecten nodosus (Linnaeus, 1758) safely inhibits arterial thrombosis after photochemically induced endothelial lesion.Designing nonsaccharide, allosteric activators of antithrombin for accelerated inhibition of factor Xa.Update on the safety and bioequivalence of biosimilars - focus on enoxaparin.On scaffold hopping: challenges in the discovery of sulfated small molecules as mimetics of glycosaminoglycans.Sulfated pentagalloylglucoside is a potent, allosteric, and selective inhibitor of factor XIaSelection of anticoagulants or antiplatelet-aggregating agents for prevention of stroke.Early invasive strategies for acute coronary syndromes.Heparin dose during percutaneous coronary intervention: how low dare we go?Early statin therapy for acute coronary syndromes.Revised guidelines for the management of non-ST-segment elevation acute coronary syndromes.Polysulfated trehalose as a novel anticoagulant agent with dual mode of action.Identification of the site of binding of sulfated, low molecular weight lignins on thrombinExopolysaccharides produced by marine bacteria and their applications as glycosaminoglycan-like moleculesSulfated, low molecular weight lignins inhibit a select group of heparin-binding serine proteases.Multicenter study on hemorrhagic risk of heparin bridging therapy for periendoscopic thromboprophylaxis.Electrochemical assay of heparin to monitor anticoagulation action in cardiovascular patientsAllosteric inhibition of factor XIa. Sulfated non-saccharide glycosaminoglycan mimetics as promising anticoagulants.Clinical potential of oral direct thrombin inhibitors in the prevention and treatment of venous thromboembolism.Antithrombotic or anti-platelet agents in patients undergoing permanent pacemaker implantationProduction of decellularized porcine lung scaffolds for use in tissue engineeringLow-molecular-weight heparins in conjunction with thrombolysis for ST-elevation acute myocardial infarction. A critical review of the literature.Reasons, procedures, and outcomes in ventriculoatrial shunts: A single-center experienceDevelopment of a population pharmacokinetic-pharmacodynamic model of a single bolus dose of unfractionated heparin in paediatric patients
P2860
Q24186324-DF8A63F7-4C35-4F6F-8C38-E6D125EE225EQ24201274-B6482072-A146-47EB-B0A5-5169D896FB93Q24240381-B741A359-04EE-4F08-BE0D-A347597833ACQ26774227-47725B71-9AAE-4917-A220-6BC6E743F1B6Q27000201-D5A81B61-B060-4071-A4BE-7847C9566AADQ30402038-369A0A72-1548-40C0-980C-9678E369D11CQ30438893-B71EB239-4DB9-459B-9A8A-91B71B6D41D7Q30840644-F479C4E4-0EB0-49A9-AFC2-F67BC3C973D1Q33342924-7CB17DE7-7181-4D78-93AF-B3B438683B54Q33344114-EDBC8C26-3A5A-4F0D-849C-F98D881CE4FDQ33370473-414A8A79-DED5-440D-BFF3-4A39EAE2B8C3Q33375346-15916C9A-912E-473F-821D-52270675C96CQ33379909-18E0A46F-A807-4C0F-8621-75F2302DA1A2Q33381803-F3BBD443-BBCC-42C1-A700-61A0D97C5DC6Q33418371-E8D77DAF-2EC2-4557-B8C1-964CDC14245AQ33432846-152D0D81-789A-41F3-A3E7-C926CA5FC6ACQ33706182-73B5F269-694C-436C-8617-D61F745105E5Q33748076-FFC5D6C7-084E-48A4-9B3A-0086CDB25B7CQ33975255-5CC071E0-F447-439E-891A-1B95DEC45BD5Q34352446-455FCADA-B9F5-4EF2-920F-563EC51F0755Q34481378-8631AF8F-4FE7-492A-BA66-073DE33A4BD2Q34547334-B22357FA-AD28-45B9-98A7-16540081CB49Q34566663-481226D1-4FBA-4D4A-8268-62ADE721D7B0Q34674187-8F2A681D-E709-4F89-8F7B-AF58D332E956Q34858594-50B49A00-4284-4850-B435-9CA00C2B0551Q34979669-B927AC6E-B686-4FA6-AEBE-5E4B96F963CEQ35152080-A6514DFB-D8AA-4496-A320-91316D14915AQ35239901-42B768EC-FC7C-4E59-9EC1-AFD35A604E1EQ35242133-673A6D9F-2151-4693-AF78-EA3342C40376Q35360491-A5D3E45B-72E5-427E-8F5B-C44022A73179Q35675434-D2F85DFE-84BE-4FD7-9EFF-F668C56AFA12Q35716789-E3C0E3E0-9564-42AE-9104-1D725442753FQ35904252-741966B7-5158-45F9-B943-48D66B7DA255Q35920828-F7783E49-11DB-4E1B-A998-B6F90E068BA8Q35977667-DA6D6125-3D21-4B65-B72C-B853738B7724Q36223073-3C341B1C-6249-48D4-8CA1-0AC9CFA93C67Q36338544-B0E15FE8-81D9-4523-A806-EA16E3D912DBQ36545687-C1F06447-3D9D-4E6B-BD9A-DD9AE8531A9CQ36661093-B673D17A-E448-4394-BC44-28BFBD3F2DE1Q37030730-B2C85301-B29B-4D94-9600-F62A7A62E31E
P2860
Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Guide to anticoagulant therapy ...... he American Heart Association.
@ast
Guide to anticoagulant therapy ...... he American Heart Association.
@en
Guide to anticoagulant therapy ...... he American Heart Association.
@nl
type
label
Guide to anticoagulant therapy ...... he American Heart Association.
@ast
Guide to anticoagulant therapy ...... he American Heart Association.
@en
Guide to anticoagulant therapy ...... he American Heart Association.
@nl
prefLabel
Guide to anticoagulant therapy ...... he American Heart Association.
@ast
Guide to anticoagulant therapy ...... he American Heart Association.
@en
Guide to anticoagulant therapy ...... he American Heart Association.
@nl
P2093
P1433
P1476
Guide to anticoagulant therapy ...... he American Heart Association.
@en
P2093
P304
P356
10.1161/01.CIR.103.24.2994
P407
P577
2001-06-01T00:00:00Z